As part of the agreement, Marksans will manufacture and supply the product to Breckenridge, who will hold US marketing and distribution rights.
Gabapentin, which was approved by the US FDA on 21 July 2011, is used to treat postherpetic neuralgia in adults.
It is also an adjunctive treatment to partial seizures in epilepsy and pediatric patients.
The product, which is available in 100mg, 300mg, and 400mg, has a $166m market, according to industry sales data.